Cognitive•Nootropic
🧠Semax
ACTH-derived nootropic peptide. Upregulates BDNF and NGF. Approved in Russia for ischemic stroke, TBI, optic nerve atrophy, and ADHD. Enhances memory, focus and neuroprotection.
Amino acids
7
Mol. weight
813.9 Da
Half-life
~20 min (active fragment longer)
Availability
On inquiry
Amino acid sequence
Met-Glu-His-Phe-Pro-Gly-ProWhat Is Semax?
Semax is a synthetic heptapeptide derived from the ACTH(4-10) sequence. Developed in Russia and approved for ischemic stroke, traumatic brain injury, optic nerve atrophy, and cognitive enhancement. It dramatically upregulates BDNF and NGF expression — making it one of the most potent nootropic peptides in preclinical research.
Key Mechanisms
- BDNF and NGF upregulation — promotes neuronal survival, synaptic plasticity and memory consolidation
- Dopamine and serotonin modulation — enhances monoaminergic neurotransmission
- Neuroprotection — reduces ischemic brain damage; promotes axonal regrowth post-injury
- Cognitive enhancement — improves working memory, attention, and information processing speed
Key References
- Dolotov OV et al. "Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus." Brain Res, 2006;1120(1):81–91.
Related in Cognitive
🧠Neuroprotective
Cerebrolysin
Brain-derived neurotrophic peptide mixture approved in 50+ countries for Alzheimer's, stroke and TBI. Neurotrophic, neuroprotective and neuroregenerative effects mediated through BDNF, NGF and GDNF pathways.
🧠Cognitive Research
Dihexa
HGF/MET signalling enhancer. Reported to be 7 orders of magnitude more potent than BDNF at inducing synaptogenesis. Blood-brain barrier penetrant. Used in dementia and cognitive decline research.
🧠Anxiolytic
Selank
Anxiolytic nootropic peptide developed in Russia. Modulates GABA-A, BDNF, and IL-6. Reduces anxiety without sedation or addiction potential. Approved in Russia for anxiety and phobia treatment.